NUBEQA – a treatment for non-metastatic castration-resistant prostate cancer

Dr. Neal D. Shore discusses the FDA approval of NUBEQA® (darolutamide) for the treatment of non-metastatic castration-resistant prostate cancer.

Neal D. Shore, MD, is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 250 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Society of Urologic Oncology Clinical Trials Consortium, and the Large Urology Group Practice Association. He also is a member of the AUA Data Committee, the Bladder Cancer Advocacy Think Tank and the editorial board of Urology Times. He has numerous articles/peer-reviewed publications and also performs peer review for more multiple journals. A graduate of Duke University Medical School, Dr. Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.

Liked it? Take a second to support healthprofessionalradio on Patreon!


Leave a Reply

You must be logged in to post a comment.